DONALD HAUSER: Open Payments
NPI 1316990674 · BELLAIRE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,863 in 181 payments from 18 companies in 2025. Trend: 2023 $18,254 · 2024 $45,280 · 2025 $20,863
Honoraria: $15,675Food & beverage: $4,411Travel & lodging: $776
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 28 | $17,316 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $640 |
| Alkermes, Inc. | 15 | $341 |
| Lundbeck LLC | 12 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $293 |
| ABBVIE INC. | 15 | $288 |
| Neurocrine BioSciences, Inc. | 9 | $240 |
| Bausch Health US, LLC | 14 | $235 |
| E.R. Squibb & Sons, L.L.C. | 10 | $208 |
| Vanda Pharmaceuticals Inc. | 9 | $202 |
Products named: Auvelity, CAPLYTA, REXULTI, ARISTADA, TRINTELLIX, VRAYLAR, INGREZZA, COBENFY.
Industry payments across TX — which companies pay providers there.
